Search
daridorexant; nemorexant (Quviviq)
Indications:
- insomnia [1] including insomnia in elderly [2]
* comorbidities that interfere with sleep such as obstructive sleep apnea, restless legs syndrome, excessive caffeine use, & prolonged daytime naps have not been studied
Dosage: 5, 10, 25, or 50 mg
Adverse effects:
- headache, somnolence, diarrhea, & fatigue
Mechanism of action:
- orexin receptor antagonist
Interactions
drug adverse effects of psychotropic agents
General
sedative/hypnotic (tranquilizer)
Database Correlations
PUBCHEM correlations
References
- Dauvilliers Y, Zammit G, Fietze I et al.
Daridorexant, a new dual orexin receptor antagonist to treat
insomnia disorder.
Ann Neurol 2020 Mar; 87:347.
PMID: 31953863
https://onlinelibrary.wiley.com/doi/full/10.1002/ana.25680
- Zammit G, Dauvilliers Y, Pain S, et al.
Daridorexant, a new dual orexin receptor antagonist, in elderly
subjects with insomnia disorder.
Neurology 2020 May 26; 94:e2222
PMID: 32341187
https://n.neurology.org/content/94/21/e2222
- Greb E
FDA OKs New Adult Insomnia Med.
Medscape. January 10, 2022
https://www.medscape.com/viewarticle/966295
- Mignot E, Mayleben D, Fietze I et al
Safety and efficacy of daridorexant in patients with insomnia disorder:
results from two multicentre, randomised, double-blind, placebo-controlled,
phase 3 trials.
Lancet Neurology. 2022. Volume 21, ISSUE 2, P125-139, Feb 1.
PMID: 35065036
https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00436-1/fulltext